Andrew Schiermeier
Vorstandsvorsitzender bei AvenCell Therapeutics, Inc.
Aktive Positionen von Andrew Schiermeier
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Kynan Pharmaceuticals | Direktor/Vorstandsmitglied | - | - |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Direktor/Vorstandsmitglied | 01.08.2021 | - |
| Vorstandsvorsitzender | 01.08.2021 | - | |
Regel Therapeutics Inc.
 Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Andrew Schiermeier
Ehemalige bekannte Positionen von Andrew Schiermeier
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Geschäftsführer | - | 21.06.2021 |
| Corporate Officer/Principal | 01.04.2018 | - | |
| MERCK KGAA | Corporate Officer/Principal | 01.05.2013 | 01.01.2016 |
| AURA BIOSCIENCES, INC. | Geschäftsführer | 01.01.2011 | 01.05.2013 |
Ausbildung von Andrew Schiermeier
| Harvard University | Doctorate Degree |
| Stanford University | Graduate Degree |
| College des Ingenieurs | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 8 |
| Deutschland | 2 |
| Frankreich | 2 |
Operativ
| Director/Board Member | 3 |
| Chief Operating Officer | 2 |
| Corporate Officer/Principal | 2 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MERCK KGAA | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| Kynan Pharmaceuticals | |
AvenCell Therapeutics, Inc.
AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Health Technology |
Regel Therapeutics Inc.
Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Health Technology |
- Börse
- Insiders
- Andrew Schiermeier
- Erfahrung
